The pharmaceutical industry has historically benefited from high profit margins for their, and over the years limited efforts have been made to change the main manufacturing from batch into continuous. However, over the last decade, as a result of an increased for more efficient and cost-effective processes, interest has grown in the application continuous manufacturing to address economical and technical issues in the pharmaceutical. This option is becoming more viable particularly with the implementation of new process technology (PAT). this paper, we present a plant-wide mathematical model inspired by a recently developed pharmaceutical pilot plant. This model is first used to simulate a basecase which typical limitations in achieving simultaneously high productivity and quality. The main quality attribute considered is the purity of the final product. To alleviate the basecase and improve the pilot plant performance, the effects of several design parameters investigated and the most critical are identified. In addition, alternative start-up scenarios To whom correspondence should be addressed1 considered to improve the transient performance of the pilot plant, particularly time to state. The environmental footprint of the pilot plant is evaluated and shown to be low. pharmaceutical manufacturing, Plant-wide dynamic model, Computer aided process, Start-up, Recycling.
No takes yet. Share an insight, caveat, or question.
Benyahia et al. (2012) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: